KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma

Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial

(2020) Ralf Gutzmer et al.   LANCET

LBA43 Spartalizumab plus dabrafenib and trametinib (Sparta-DabTram) in patients (pts) with previously untreated BRAF V600–mutant unresectable or metastatic melanoma: Results from the randomized part 3 of the phase III COMBI-i trial

(2020) P. Nathan et al.   ANNALS OF ONCOLOGY

FDA analysis of depth of response (DpR) and survival across 10 randomized controlled trials in patients with previously untreated unresectable or metastatic melanoma (UMM) by therapy type.

(2019) Christy Osgood et al.   JOURNAL OF CLINICAL ONCOLOGY

The anti–PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600–mutant melanoma: Updated efficacy and safety from parts 1 and 2 of COMBI-i.

(2019) Georgina V. Long et al.   JOURNAL OF CLINICAL ONCOLOGY

Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients

(2019) Ryan J. Sullivan et al.   NATURE MEDICINE

Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma

(2019) Paolo Antonio Ascierto et al.   NATURE MEDICINE

Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma

(2019) Antoni Ribas et al.   NATURE MEDICINE

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma

(2019) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Impact of depth of response on survival in patients treated with cobimetinib ± vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM

(2019) Karl D. Lewis et al.   BRITISH JOURNAL OF CANCER

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2019) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials

(2017) Dirk Schadendorf et al.   EUROPEAN JOURNAL OF CANCER

Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial

(2017) Georgina V Long et al.   LANCET ONCOLOGY

Targeted agents and immunotherapies: optimizing outcomes in melanoma

(2017) Jason J. Luke et al.   Nature Reviews Clinical Oncology

Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab

(2016) Benjamin Weide et al.   CLINICAL CANCER RESEARCH

Progression-free survival landmark analysis: a critical endpoint in melanoma clinical trials

(2016) Paolo A Ascierto et al.   LANCET ONCOLOGY

Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma

(2016) Marcel A. Deken et al.   OncoImmunology

Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF V600E melanoma

(2015) Siwen Hu-Lieskovan et al.   Science Translational Medicine

Late divergence of survival curves in cancer immunotherapy trials: interpretation and implications

(2013) Fredrik B. Thorén et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma

(2013) D. T. Frederick et al.   CLINICAL CANCER RESEARCH

Statistical issues and challenges in immuno-oncology

(2013) Tai-Tsang Chen   Journal for ImmunoTherapy of Cancer

Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma

(2011) James S. Wilmott et al.   CLINICAL CANCER RESEARCH

Targeted Therapies to Improve Tumor Immunotherapy

(2008) J. Begley et al.   CLINICAL CANCER RESEARCH

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER